800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases. In April this year, the FDA approved ImmunityBio's Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors The analyst writes, “Anktiva has the potential to revolutionize cancer immunotherapy by enhancing the efficacy of immune-based treatments, particularly in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).” The analyst writes that clinical trials have shown that Anktiva delivers high complete response rates and long-term disease control, indicating its potential to enhance patient outcomes. This could minimize the need for radical surgeries while broadening the range of available immuno-oncology treatments. The analyst initiates with a Buy rating and a price target of $30, an ast
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.MarketBeat
- ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! FinanceYahoo! Finance
- ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituBusiness Wire
- ImmunityBio announces collaboration with Beigene [Seeking Alpha]Seeking Alpha
- ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung CancerBusiness Wire
IBRX
Earnings
- 11/12/24 - Beat
IBRX
Sec Filings
- 2/13/25 - Form 8-K
- 2/12/25 - Form 4
- 2/12/25 - Form 4
- IBRX's page on the SEC website